Facility Design and Expansion: Commissioning for Innovation - Many biotech facilities consume more than tenfold the amount of energy used by other institutions. Design a space that is right for your

ADVERTISEMENT

Facility Design and Expansion: Commissioning for Innovation
Many biotech facilities consume more than tenfold the amount of energy used by other institutions. Design a space that is right for your business.


BioPharm International
Volume 19, Issue 5

Consider that both the vivarium and pilot facility should have 100 percent back-up, because their operations are time-sensitive and critical to the central function of the entire organization. In addition to standby equipment, strategies to share equipment or reduce services for less critical functions are often a cost effective and dependable means of ensuring 100 percent uptime for critical facilities. For example, use a laboratory air handling unit to back up a vivarium system in case of failure or maintenance, provided that the laboratory function can accept a temporary reduction in service.

A number of additional system redundancies are also required to ensure that the critical elements of a biotechnology facility, specifically the laboratory space, are adequately prepared for the event of an unexpected power failure or system shut down. This includes information technology safeguards, security, fire and life-safety equipment, and various procedures for operations, maintenance, monitoring, controls, and disaster recovery.

As the biotechnology industry continues to play an increasing role in the delivery of cutting-edge products and technologies, modern biotechnology firms continue to pursue new research programs and adopt modern technologies that will help them remain agile and ahead of the intense competition. Their success in implementing these new programs and technologies in the years ahead will be contingent upon the delivery of flexible and energy efficient design concepts that allow cost-effective expansion efforts.

Mark N. Yakren, PE, is Senior Vice President, Syska Hennessy Group, 11 West 42nd St., New York, NY, 10036, tel 800.328.1600; fax 212.556.3242,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here